Albendazole is a broad-spectrum anthelmintic medication belonging to the benzimidazole class of compounds. It is employed primarily for the treatment and control of a variety of parasitic worm infections in humans and veterinary medicine.
Chemical and Pharmacological Profile
- IUPAC name: methyl 5‑(propylthio)-1H‑benzo[d]imidazol‑2‑ylcarbamate
- Molecular formula: C₁₂H₁₅N₃O₃S
- Molecular weight: 265.33 g·mol⁻¹
- Physical state: White to off‑white crystalline powder; poorly soluble in water but more soluble in organic solvents such as ethanol and dimethyl sulfoxide.
- Mechanism of action: Albendazole exerts its antiparasitic effect by selectively binding to the β‑tubulin of helminths, inhibiting microtubule polymerization. This disruption impairs glucose uptake, depletes glycogen stores, and ultimately leads to parasite immobilization and death.
Clinical Uses
Albendazole is indicated for the management of several helminthic infections, including but not limited to:
| Indication | Common causative parasites |
|---|---|
| Neurocysticercosis | Taenia solium larvae |
| Hydatid disease (cystic echinococcosis) | Echinococcus granulosus |
| Ascariasis | Ascaris lumbricoides |
| Hookworm infection | Ancylostoma duodenale, Necator americanus |
| Trichuriasis | Trichuris trichiura |
| Strongyloidiasis | Strongyloides stercoralis |
| Lymphatic filariasis (as adjunct) | Wuchereria bancrofti, Brugia malayi |
| Giardiasis (off‑label) | Giardia lamblia |
In veterinary practice, albendazole is used to control gastrointestinal nematodes, liver flukes, and other parasitic infections in livestock, companion animals, and wildlife.
Pharmacokinetics
- Absorption: Oral bioavailability is modest; it increases markedly when taken with fatty meals due to enhanced dissolution.
- Distribution: After absorption, albendazole is rapidly metabolized in the liver to its active sulfoxide metabolite (albendazole‑sulfoxide), which achieves systemic circulation and is responsible for most therapeutic effects.
- Metabolism: Primarily hepatic via cytochrome P450 enzymes (CYP3A4 and CYP1A2).
- Elimination: Albendazole‑sulfoxide is excreted in urine (≈30–40 %) and feces (≈50 %); the terminal half‑life ranges from 8 to 12 hours in adults.
- Pregnancy and lactation: Classified as Pregnancy Category C (US) or D (EU) depending on jurisdiction; risk–benefit assessment is required, particularly for neurocysticercosis treatment.
Dosage Forms
Available as oral tablets (commonly 200 mg and 400 mg strengths) and as a suspension for pediatric use. Dosage regimens vary by indication, patient age, weight, and severity of infection. For example:
- Neurocysticercosis: 15 mg/kg/day in divided doses for 7–30 days, sometimes followed by a maintenance course.
- Hydatid disease (pre‑surgical): 10 mg/kg/day for 28 days.
Adverse Effects and Contraindications
Commonly reported side effects include:
- Gastrointestinal disturbances (nausea, abdominal pain, diarrhea)
- Elevated hepatic transaminases (transient)
- Headache and dizziness
Rare but serious adverse events may involve:
- Hepatotoxicity (hepatitis, jaundice)
- Bone marrow suppression (leukopenia, pancytopenia)
- Alopecia (hair loss)
Contraindications: known hypersensitivity to albendazole or other benzimidazoles, and severe hepatic impairment. Caution is advised in patients with pre‑existing liver disease, hematologic disorders, or concomitant use of drugs that are strong inducers or inhibitors of CYP3A4.
Drug Interactions
- CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce plasma concentrations of albendazole‑sulfoxide, diminishing efficacy.
- CYP3A4 inhibitors (e.g., ketoconazole) can increase systemic exposure, potentially heightening toxicity.
- Concurrent use with other hepatotoxic agents warrants close monitoring of liver function tests.
Regulatory and Patent History
Albendazole was first synthesized in the late 1970s and introduced into clinical practice in the early 1980s. It is listed on the World Health Organization’s Model List of Essential Medicines. Various generic manufacturers produce the drug worldwide; several brand names exist, such as Albenza (USA), Zentel (Europe), and Albex (India).
Research and Development
Ongoing investigations explore albendazole’s efficacy against emerging parasitic strains, its potential anti‑cancer properties (via tubulin inhibition), and novel delivery systems (e.g., nanocarriers) aimed at improving bioavailability and reducing dosing frequency.
References
(Encyclopedic entries typically cite peer‑reviewed sources; for brevity, specific citations are omitted here but include standard pharmacology texts, WHO technical reports, and FDA drug labeling.)